Neither BPC 157 nor TB 500 is approved by the FDA for human use or for diagnosing, treating, curing, or preventing any disease
Five years after treatment or remission is used as a conservative review window rather than a proven biological cutoff
Ethics declarations Competing Interests The authors declare no competing interests
Some users note transient changes in appetite or sleep patterns during the first few days of use
agent model), there are prostaglandins analoguesethanol model (Robert, 1979) relationships, NSAIDsacetic acid model (Okabe and Amagase, 2005) relationships, dopamine agonistscysteamine model (Selye and Szabo, 1973) relationships, and H 2 blockerscysteamine model (Selye and Szabo, 1973) relationships